ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Nov 18, 2022 21:00 JST
Source:
China Medical System Holdings Ltd.
China Medical System (867.HK) S&P Global CSA Score Achieved Significant Improvement, Leading the Industry Globally
SHENZHEN, CHINA, Nov 18, 2022 - (ACN Newswire) - Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG) scores for China Medical System Holdings Limited ("CMS" or the "Group"). CMS achieved a significant improvement with a score of 53 in 2022 from 36 in 2021, surpassing 92% of the global peers and being significantly ahead of the industry average. This result shows the Company's outstanding achievement from its active integration of ESG governance into strategic development and daily operation.
S&P Global CSA is the global leading assessment tool of corporate sustainability practices initiated by S&P Global. S&P Global CSA provides comprehensive evaluation on corporate sustainability performance, and the Group's identification and management abilities of potential opportunities and challenges by considering factors, such as corporate economy and governance, environment protection, and social responsibility. S&P Global CSA has been regarded, by stakeholders, as one of the most important references for making business or investment decisions.
Based on a well-established, scientific and effective ESG governance structure, CMS has been continuously improving its overall operations with the concept of sustainable development. Its latest S&P Global CSA-ESG scores indicated the Group has achieved significant improvements in several issues including Human Rights, Occupational Health & Safety, Supply Chain Management, Product Quality Management, Information Security & Cyber Security, Environment Policy & Management Systems, Addressing Cost Burden and Improving Access to Healthcare. Especially, the Group received excellent scores in Marketing Practices, Product Quality Management, and Addressing Cost Burden.
Adhering to compliant operations, CMS has built an honest, efficient, and open operational culture via a solid internal management system. By continuously enhancing its innovative product incubation platform and fully leveraging its strengths, the Group promotes diversified collaborative R&D and continues to build a pharmaceutical ecosystem in a collaborative setting for the benefit of all stakeholders, to improve pharmaceutical R&D efficiency, and constantly offer patients with accessible, affordable, and quality products. In the future, upholding visionary corporate mission and responsibility, CMS said it will continuously enhance its corporate governance, environment control practices, and social responsibility fulfillment, and promote the integration of ESG concepts into the Group's strategy, striving to be the leading sustainable pharmaceutical company in China.
Media Contact
Media Team, CMS
Email:
ir@cms.net.cn
Website:
http://www.cms.net.cn/
Source: China Medical System Holdings Ltd.
Source: China Medical System Holdings Ltd.
Sectors: Healthcare & Pharm, MedTech
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Mazda Production and Sales Results for August 2024
Sep 27, 2024 17:20 JST
Honda Issues Integrated Report - "Honda Report 2024"
Sep 27, 2024 15:37 JST
Hitachi Becomes First Oracle Partner in Japan to Win Regional Best in Class Award in the Customer Success Category in the 2024 Oracle Partner Awards
Sep 27, 2024 14:19 JST
Mitsubishi Corporation Strengthens the Partnership with PETRONAS, Reinforcing Confidence in LNG Operations in the Region
Sep 27, 2024 13:39 JST
MHI Completes Production of the Core Stage of the Final H-IIA Launch Vehicle (No. 50)
Sep 26, 2024 12:00 JST
A2Z and Nayax Capital Sign Framework Agreements to Enable Global Financing for the Sale or Lease of Cust2Mate Smart Carts Integrated with Nayax's Solutions
Sep 25, 2024 22:00 JST
Osaka Gas and MHI to Implement the CO2NNEX Digital Platform for Managing and Transferring the Environmental Value of e-Methane at Expo 2025 Osaka, Kansai, Japan
Sep 25, 2024 15:11 JST
Hitachi Rail Unveils the 'HMAX' AI Solution, Accelerated by NVIDIA, to Optimize Trains, Signaling and Infrastructure
Sep 25, 2024 13:05 JST
Overview of Honda Exhibits at JAPAN MOBILITY SHOW BIZWEEK 2024
Sep 24, 2024 18:32 JST
Tosha Schareina Wins FIM E-Xplorer World Cup Men's Category
Sep 24, 2024 18:16 JST
Mazda to open new R&D office in Azabudai Hills in early summer 2025
Sep 24, 2024 16:25 JST
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
Sep 24, 2024 16:06 JST
Valuufy CEO to present at the UN Science Summit (SSUNGA79)
Sep 24, 2024 16:00 JST
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
Sep 24, 2024 15:01 JST
Mitsubishi Corporation, KDDI CORPORATION, Lawson, Inc. Launching an Initiative to Transform into "Next-generation Convenience Store"
Sep 20, 2024 18:02 JST
Hitachi Rail is innovating and delivering transformative 5G digital signalling
Sep 20, 2024 16:47 JST
Olympus Launches New 4K Camera Head for Urological Endoscopy
Sep 20, 2024 15:00 JST
Honda to Relocate the Base of its Rugby Team Activities
Sep 19, 2024 15:05 JST
Renewal of Compact CO2 Capture System "CO2MPACT(TM)" Series
Sep 19, 2024 14:35 JST
The world's first commercial copper die-cast rotor for railway traction motors
Sep 19, 2024 13:57 JST
More Latest Release >>
Related Release
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
September 24 2024 21:00 JST
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023
August 16 2024 13:00 JST
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
August 05 2024 22:00 JST
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
July 16 2024 20:00 JST
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
June 25 2024 20:00 JST
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
June 18 2024 18:45 JST
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
April 23 2024 22:00 JST
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
April 01 2024 20:30 JST
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
March 28 2024 10:23 JST
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
February 04 2024 09:00 JST
More Press release >>